The project “Tridiag – New diagnostic tools in transplantation medicine”
Transplantation is currently the main clinical option for the curative or palliative treatment of a broad range of diseases. However the risks of complication exist. In bone marrow transplants, one of the main complications is the graft-vs.-host (GvH) reaction. In kidney transplantation, graft rejection is the main problem.
The MIC histocompatibility system, discovered by the team of Strasbourg, is an excellent candidate to partly explain the pathogenesis of the GvH reaction and the graft rejection.
The goal of this cross-border project is to validate two diagnostic tests based on MIC molecules:
– a molecular diagnostic test to evaluate compatibility at the DNA level between donors and recipients for bone marrow transplants,
– and a serology diagnostic test to dose anti-MIC antibodies in the serum of kidney transplant patients.
These tests are aimed to be used in routine clinical practice in order to reduce the incidence of the GvH reactions in bone marrow transplants as well as graft rejection episodes in kidney transplants, thereby helping to alleviate the burden of these extremely serious complications for patients.
